MedPage Today July 30, 2024
— Use for diabetes tied to fewer medical visits for tobacco use disorder versus other antidiabetics
Among patients with type 2 diabetes and tobacco use disorder (TUD), use of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy) was associated with a reduced risk of medical encounters for TUD compared with other diabetes medications, according to an emulation target trial.
Using a nationwide population-based database of electronic health records, the strongest association with a reduced risk of medical encounters for TUD diagnosis, smoking cessation medication prescriptions, and smoking cessation counseling was observed when semaglutide was compared with insulins (HR 0.68, 95% CI 0.63-0.74), reported Nora D. Volkow, MD, director of the National Institute on Drug Abuse, and colleagues.
The association was weakest,...
Today's Sponsors
Today's Sponsor